First-in-Human Trial of ACP-501 for Familial LCAT Deficiency Initiated
A clinical trial has been initiated to evaluate the safety and efficacy of ACP-501, a recombinant human LCAT, in a patient with familial LCAT deficiency.
Therapeutic Area
Therapeutic area intelligence for Enzyme Replacement Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.